Comparison of the Effect on Blood Pressure Variability in acute ischemic stroke: Fimasartan vs. Valsartan

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003254

Enrollment

Registered

2018-10-11

Start date

2015-07-09

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Randomization Arrangements of the two groups are randomly assigned 1: 1 randomly assigned by the computer at the clinical trial center. Fimasartan group (n = 40) and Valsartan group (n = 40) by

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Adults older than 30 • Patients with acute ischemic stroke who have symptoms described by diffusion weighted image and who are within 28 days after onset 7 • Patients whose screening systolic blood pressure is greater than 140 mmHg or who are taking antihypertensive drugs • If the neurological deterioration stabilizes during screening and more than 48 hours have elapsed

Exclusion criteria

Exclusion criteria: • Hemorrhagic stroke patients • Patients with somatic hypotension • Severe stroke patients - Patients with a NIHSS (NIH Stroke Scale) score of 16 or greater • Patients whose mean blood pressure during screening was not adjusted to more than 200 mmHg • Patients allergic to hypertensive drugs • Hematologic tests show abnormalities such as: - Abnormal liver function abnormalities (SGOT, SGPT, total bilirubin, if more than twice the normal value) - Anemia (hemoglobin <8mg / dl) or thrombocytopenia (<100,000 / mm3) - kidney failure (serum creatinine> 2.0 mg / dl) • Patients who are pregnant or lactating • Patients with suspected secondary hypertension • Patients that researchers consider inappropriate

Design outcomes

Primary

Measure	Time frame
difference of mean and standard deviation of the entire 24-h period and separately for the daytime period and the nighttime period between two groups after treatment, which is measured by ambulatory blood pressure monitoring.	—

Secondary

Measure	Time frame
difference of other parameters for blood pressure variability such as weighted standard deviation, coefficient of variation, average real variability. Primary and secondary outcomes were evaluated at baseline and 8 weeks	—

Countries

Korea, Republic of

Contacts

Public ContactDong Hoon Shin

Gachon University Gil Medical Center

dr.donghoon.shin@gmail.com+82-32-460-3346

Outcome results